FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of advanced molecular imaging agents. Initially, its efforts are concentrated on cardiovascular applications within the United States market. The company's pipeline features two notable product candidates: BFPET: An imaging agent designed for stress-testing patients with suspected or confirmed coronary artery disease (CAD), which has successfully completed its Phase I clinical trial.